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Objectives: To investigate the eﬀect of a percutaneous radiofrequency
(RF) heat lesion compared with a sham procedure, applied to the
lateral branches of L5, S1, S2, S3, and S4 nerve roots.
Materials and Methods: Sixty patients aged 18 years and above with a
medical history and physical examination suggestive for sacroiliac joint
pain and a reduction of 2 or more on a numerical rating scale (NRS, 0
to 10) after a sacroiliac joint test block were included in this study.
Treatment group: percutaneous RF heat lesion at the lateral branches
of S1, S2, S3, and S4 nerve roots and the posterior ramus dorsalis of
L5; sham group: same procedure as the treatment group except for the
RF heat lesion. Primary outcome measure: pain reduction (NRS).
Secondary outcome measure: Global Perceived Eﬀect.
Results: No statistically signiﬁcant diﬀerences in pain level over time
between the groups (GroupPeriod) (F1,58=0.353; P=0.56) nor
within the treatment Group (F1,58=0.212; P=0.65) were found.
The Period factor, however, yielded a signiﬁcant diﬀerence
(F1,58=61.67; P<0.001), that is, when pooled together the mean
pain level of the patients was signiﬁcantly reduced at T1 compared
with T0. In the crossover group, 42.1% experienced a reduction in
NRS of 2 or more at 1 month (P=0.65). No statistically signiﬁcant
diﬀerence in satisfaction over time between the groups was found
(F1,50=2.1; P=0.15). The independent factors Group (F1,50=2.02;
P=0.16) and Period (F1,50=0.95; P=0.33) also showed no stat-
istically signiﬁcant diﬀerence. The same applies to recovery: no
statistically signiﬁcant GroupPeriod eﬀect (F1,51=0.09; P=0.77)
was found, neither an eﬀect of Group (F1,51=0.004; P=0.95) nor
of Period (F1,51=0.27; P=0.60).
Discussion: The hypothesis of no diﬀerence in pain reduction or in
Global Perceived Eﬀect between the treatment and sham group
cannot be rejected.
Level of Evidence: Level 1A.
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In patients with sacroiliac (SI) joint pain (constituting 10%to 38% of patients with chronic low back pain1–3),
questions arise concerning the persons who might be more
susceptible for these problems, how the diagnosis should be
made, and what comprises optimal treatment. For diag-
nosing SI joint problems, besides a suggestive medical his-
tory and a physical examination,4–8 an intra-articular
injection with local anesthetics is still being used. Every step
has its limitations and the whole diagnostic cascade should
lead toward suﬃcient evidence for treatment of the SI joint.
Several types of treatment for trying to diminish SI joint
pain are described in the literature, one of them is applying
radiofrequency (RF) current to the nerves that provide the
innervation.9,10 Several studies describe a success ratio
between 64% and 80%.11–13 The application of RF current
can be provided in several ways (pulsed or continuous, side of
the lesion, number of lesions),3,10,14–17 the practicality of the
application must always be considered. More recently evi-
dence emerged about the use of cooled RF current in pro-
viding a signiﬁcant and long-lasting pain relief.18–23
The Simplicity III probe (Neurotherm, Wilmington, MA)
is a multielectrode RF probe that has a unique design that
allows for positioning using a single percutaneous entry point.
With this procedure the lateral branches of S1, S2, S3, and S4
are targeted at the same time (a L5 dorsal root ramus RF
lesioning is performed separately). There are no randomized-
controlled trials (RCTs) available concerning the use of this
device in diminishing SI joint pain. In this randomized sham-
controlled double-blind multicenter clinical trial (Current
Controlled Trials ISRCTN45914408) the percutaneous RF
treatment of SI joint pain with this probe was evaluated and
compared with a sham procedure. A crossover was provided
for the sham-operated group after 3 months if no signiﬁcant
pain relief was obtained.
MATERIALS AND METHODS
Study Design
We conducted a randomized sham-controlled double-
blind multicenter clinical trial in patients with SI joint pain
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for >3 months. The medical ethics committee from Eras-
mus University Medical Centre approved the protocol.
Written informed consent was obtained from all
participants.
Participants
Suitable patients for the study were recruited from a
population of patients referred to the multidisciplinary pain
centers of 2 general hospitals with reports of ongoing low
back pain for >3 months. Conservative care (rest, analgesics,
and physiotherapy) had failed to improve their burden. These
patients were managed according to the ﬂowchart presented
in Figure 1. When a SI joint problem was suspected, details of
medical history, physical examination, and—if necessary—
additional tests4–7 leading, either wholly or in part, to the
diagnosis of SI joint pain can be found in Table 1, patients
met the inclusion and exclusion criteria24 (Table 2), and if the
test SI joint injection with local anesthetics was positive
(decrease in numerical rating scale [NRS] of 2 or more on
a 0 to 10 point scale26), the patient was eligible for the
RCT. Each patient received a general brochure containing
information concerning scientiﬁc research involving human
subjects (Ministry of Health, Welfare and Sports27) and a
brochure (including the questionnaires) explaining the com-
plete procedure. After giving written informed consent
patients were enrolled in the study.
Study Interventions
Test SI joint injection: the injection was performed
under ﬂuoroscopy with a 10-cm Sluijter-Mehta Kit (SMK)
needle (Cotop via Neurotherm). The patient lies in the
prone position on the operating table with a pillow under
the pelvis. From the anteroposterior view, the c-arm is
rotated contralaterally until the medial cortical line of the
posterior articulation is in focus. Local anesthesia with
1mL lidocaine 2% was given for skin inﬁltration. Needle
insertion is 1 to 2 cm cranially from the lower border of the
SI joint at the level of the zone of maximal radiographic
translucency. Introduction of the needle into the SI joint is
characterized by a change in resistance. On a lateral view,
the needle tip should appear anterior to the dorsal border of
the sacrum. The SI joint was injected with a total of 3mL
lidocaine 2%.
RF heat lesion of the ramus dorsalis of L5 and lateral
branches of S1, S2, S3, and S4 with a RF probe with 3
independent active electrodes versus sham: when patients
were candidates for the trial they were randomized in 2
study groups.
(1) Treatment group: monitoring according to American
Society of Anesthesiologists House of Delegates Stand-
ards for Basic Anesthetic Monitoring.28 Continuous
intravenous propofol, target-controlled infusion
(0.5 mg/mL), and remifentanyl (0.05 mg/kg/min). Con-
tinuous oxygen 15L/min (nonrebreather mask and
bag). The patient lies in the prone position on the
operating table with a pillow under the pelvis. Skin
inﬁltration with 1mL lidocaine 2% per level. The skin
entry point for the RF probe with 3 independent active
electrodes is identiﬁed at the ipsilateral, lateral, inferior
border of the sacrum, and 1 cm lateral of and below the
S4 foramen. Inﬁltration over the course of the RF
probe with 3 independent active electrodes with 10mL
lidocaine 2%, staying lateral to the sacral foramen, in
contact with the sacrum, and medial to the SI joint.
Inserting and advancing RF probe, maintaining
continuous contact with the sacrum on a cephalad
and slightly lateral line, staying lateral to the sacral
foramen, medial to the SI joint, and ventral to the ilium,
until contact with the sacral ala prevents further
advancement. Percutaneous RF heat lesion (851C, each
step 90 s, total of 5 steps) with a RF lesion generator
(NT2000; Neurotherm) at the lateral branches of S1,
S2, S3, and S4 nerve roots. Percutaneous RF heat lesion
(851C for 90 s, same lesion generator) of the L5 dorsal
root primary ramus with a 10-cm SMK needle, placed
to lie in contact with the S1 superior articular process
just slightly above the groove formed between the
superior articular process and sacral ala; then advanced
with needle position conﬁrmed using ﬂuoroscopy
(anteroposterior and lateral view) and motor stimula-
tion (2Hz and at least 1V).
(2) Sham-operated group: same procedure as in treatment
group except for the RF heat lesions.
A crossover was provided for the sham-operated
group after 3 months if no signiﬁcant pain relief was
obtained.
FIGURE 1. Study flowchart. NRS indicates numerical rating
scale; RCT, randomized-controlled trial; RF, radiofrequency.
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Outcomes
The main study parameter was pain reduction
NRS25,29–32). The 0 to 10 verbal NRS-11 is a tool that
enjoys widespread clinical use due to its ease of
administration. When using the NRS-11 patients are asked
to rate their pain on a scale from 0 to 10, where 0 represents
“no pain” and 10 represents “the worst pain possible,”
using whole numbers (11 integers including zero). Often the
value of “4” is used to conﬁrm clinical nursing judgment as
to the need for further intervention or documentation that
the patient’s goals for analgesia have been achieved.
The secondary study parameter was Global Perceived
Eﬀect (GPE).33–35 The type of rating of perceived eﬀect is a
“transition scale” or GPE scale. The GPE scale asks the
patient to rate, on a numerical scale, how much their con-
dition has improved or deteriorated at some predeﬁned
timepoint. The GPE has several qualities that make it an
appealing tool for use in clinical practice and research;
being a single question, it is easy and quick to administer
and the results are seemingly simple to interpret. Such
scales have been recommended for use as a core outcome
measure for chronic pain trials and been advocated to
increase the relevance of information from clinical trials to
clinical practice.33
Follow-up
The results of the crossover group were analyzed
separately, and compared with those who received the
actual treatment in the ﬁrst case. Time periods for follow-
up are presented in Table 3. Both groups received graded
activity36,37 physiotherapy, which constitutes an individual,
submaximal, gradually increased exercise program, with an
operant-conditioning behavioral approach, based on the
results of the tests and the demands of the patient’s work.
Statistical Considerations
Diﬀerence in patients’ sex between the experimental
groups was analyzed using the Fisher exact test. Diﬀerence
in age was analyzed using the independent samples Mann-
Whitney U test; and the diﬀerence in body mass index using
the independent samples t test. The data on the NRS-11,
GPE (subscales “Satisfaction” and “Recovery”) were ana-
lyzed by means of multivariate analysis of variance
(MANOVA) for repeated measurements using as inde-
pendent variables, Group (treatment and sham) and Time
(in case of the NRS-11 Period T0-T1, in case of the GPE
subscales Period T1-T2 as independent variables).
For the skewed distributed variables we nevertheless
decided to use MANOVA for repeated measurements
analysis of variance. We did so, because, although the
MANOVA test requires that each dependent variable
entered into the analysis be normally distributed it can still
be used in case of skewly distributed dependent variable(s).
The Monte Carlo experiments have shown that for sample
size 3 or 5 it is still possible to analyze leptokurtic,
TABLE 1. Details About Medical History, Physical Examination,
and Additional Tests in Patients Leading, Either Wholly or in Part,
to the Diagnosis of Sacroiliac Joint Pain4–7
Diagnostic Criteria for SI Joint Pain
Medical history
1. Unilateral pain
2. Patient ﬁnger points to the location of the pain
3. Pain produced or increased when rising from sitting
4. Direct trauma to the SI joint
5. Buttock pain while turning over in bed
6. Sitting on opposite buttock
7. Hip feels unstable or has given way, some patients fall
8. Pain radiating into the groin or thigh
9. Sciatica (often S1)
10. Pregnancy, giving birth
Physical examination
1. Sitting examination shows no reﬂex, motor, or sensory signs in
the legs
2. Straight leg raising (Lase`gue) negative between 30 and 70
degrees of passive ﬂexion
3. Distraction (Gapping) test
4. Compression test
5. Sacral thrust test
6. Posterior shear (thigh thrust) test
7. Pelvic torsion (Gaenslen’s) test
8. Cranial shear test
9. Patrick-Faber test
10. Bilateral internal rotation of the hip/unilateral rotation of the
hip painful at SI joint(s)
11. Drop test
12. Yeoman’s test
Additional tests (if available and/or necessary)
1. X-ray pelvis anteroposterior
2. CT
3. MRI
4. Diagnostic SI joint block
CT indicates computed tomography; MRI, magnetic resonance imaging;
SI, sacroiliac.
TABLE 2. Inclusion and Exclusion Criteria24 for Patients With SI
Joint Pain Eligible for RCT
Inclusion
1. Age 18 y or older
2. Anamnesis and physical investigation suggestive of SI joint
pain
3. Decrease in NRS of 2 or more/10 on diagnostic SI joint block
Exclusion
1. Presence of red ﬂags25
2. Lumboradicular syndrome
3. Aspeciﬁc low back pain
4. Corpus vertebrae problem
5. Progressive neurological defecits
6. Major psychiatric disorder (according to psychiatrists
opinion)
7. Anticoagulation cannot be stopped
8. Active infection
9. Pain in other parts of the body that is more severe
10. Allergies to any medication used in the study
11. Pregnancy
12. Communication (language) diﬃculties (according to
physicians opinion)
TABLE 3. Time Periods for Follow-up
Period Description
T0 Day of ﬁrst consultation: medical history, physical
examination, additional tests if necessary. Excluding red
ﬂags,25 aspeciﬁc low back pain and corpus vertebrae
problems. Obtaining NRS
T1 1 month after treatment: NRS and GPE
T2 3mo after treatment: NRS, GPE
T1c 1mo after treatment for crossover group: NRS and GPE
T2c 3mo after treatment for crossover group: NRS, GPE
GPE indicates Global Perceived Eﬀect; NRS, Numerical Rating Scale.
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rectangular, J-shaped, moderately, and markedly skewed
distributions. These experiments demonstrated that the
empirically determined rejection region of the F-dis-
tribution would be no larger than a=0.08 when the usual
5% rejection is used.38
The percentage of patients requesting crossover and
subsequently reporting a signiﬁcant pain relief was analyzed
using the One-Sample Binomial Test (reference probability,
0.5). Only patients in the sham group could switch to the
intervention.
The sample size was computed using the NRS-11 as
the primary outcome parameter. A statistically detectable
and clinically relevant within/between interaction eﬀect size
(f(V)) of 0.2 on this scale was chosen. The power of the
study (1b) was chosen to be 0.8, an allocation ratio of 1:1,
and the 2-sided level of signiﬁcance (a) to be 0.05. The
required a priori total sample size computed by this method
is 60.
Data were analyzed using SPSS for Windows, version
22 (International Business Machines [IBM] Corporation,
Software Group, NY). The primary comparison was done
at T1.
Blinding
On the basis of the required sample size calculation, 60
envelopes (30 “treatment group” and 30 “sham group”)
were prepared, sealed, mixed, and placed together in a box.
Patients chose an envelope randomly. Patients and their
pain physicians were completely unaware of the content of
the envelope during any stage (or T2 in case of sham pro-
cedure without reduction in NRS of 2 or more) of the
investigation. The pain research nurse was the only one
aware of the contents and performed the treatment
accordingly. Regarding the RF lesion generator, all sound
indicators were turned oﬀ and the generator itself was vis-
ually hidden from the patient by means of a linen cloth,
hung between 2 metal infusion poles. The pain physician
left the operating theater when the actual treatment (RF
current or sham) took place. The same time period was
taken for an actual—or a sham treatment.
RESULTS
Patients were included and treated between February
2012 and June 2014. Of 79 eligible patients (1 patient
entered the study without a written informed consent) a
total of 19 patients resigned due to various reasons: no
signiﬁcant pain reduction after diagnostic block (9), no
more pain after diagnostic block (2), afraid of unemploy-
ment (1), not enough time (1), shortly after signing the
informed consent form, no reason speciﬁed (1), second
opinion (1), cumbersome sedation (1), chronic pain turned
bearable (1), fear of needles (1), and without reporting a
cause (1).
The ﬂowchart of the progress through the phases of
the RCT is presented in Figure 2. The demographic data of
the treatment and sham groups are presented in Table 4.
There was no statistically signiﬁcant diﬀerences between the
parameters of the groups.
No statistically signiﬁcant diﬀerence in pain level over
time between the groups (GroupPeriod) (F1,58=0.353;
P=0.56) nor in the factor Group (F1,58=0.212; P=0.65)
was found. The Period factor, however, yielded a signiﬁcant
diﬀerence (F1,58=61.67; P<0.001), that is, when pooled
together the mean pain level of the patients was
signiﬁcantly reduced at T1 compared with T0 (Fig. 3). In
the crossover group, 8 of 19 patients experienced a reduc-
tion in NRS of 2 or more at 1 month crossover (P=0.65).
No statistically signiﬁcant diﬀerence in satisfaction over
time between the groups (GroupPeriod) was found
(F1,50=2.1; P=0.15). The independent Group (F1,50=2.02;
P=0.16) and Period factors (F1,50=0.95; P=0.33) also
showed no statistically signiﬁcant diﬀerence (8 missing cases on
T2). The same applies to recovery: no statistically signiﬁcant
GroupPeriod eﬀect (F1,51=0.09; P=0.77) was found,
neither an eﬀect of Group (F1,51=0.004; P=0.95) nor of
Period (F1,51=0.27; P=0.60) (7 missing cases on T2)
(Table 5).
FIGURE 2. Flow diagram of the progress through the phases of
the randomized-controlled trial. RF indicates radiofrequency.
TABLE 4. Demographic Data of the Treatment and Sham
Groups
Parameters Treatment Sham P
Age (median [IQR]) (y) 59.5 (27) 62 (18) 0.89
BMI (mean [SD]) (kg/m2) 28.1 (5.2) 28 (4.9) 0.87
Male sex (n [%]) 5 (16.7) 5 (16.7) 1
Female sex (n [%]) 25 (83.3) 25 (83.3) 1
White race (n [%]) 30 (100) 30 (100) 1
BMI indicates body mass index; IQR, interquartile range (25, 75).
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During the trial we noted 1 unexpected and unsus-
pected serious adverse event, due to a fall from the stairs
during the follow-up period.
DISCUSSION
In this RCT the proportion of patients who reported
signiﬁcant pain relief (NRSZ2) after the sham procedure
was even higher (but not statistically signiﬁcant) than those
after the actual treatment. In the crossover group (3mo
after the sham procedure) the number of people that
demonstrated a statistically signiﬁcant reduction after the
RF treatment was 42.1%, which equals the number of
positive results (43.3%) from the primary treatment group.
The number of positive SI joint test blocks was 86.1%
(62/72 blocks), which is higher than expected when con-
sidering the available literature.1,2,8 Possible reasons could
be (the combination of) multidisciplinary assessment, rating
of the decrease in NRS as a result of the test injection with
local anesthetics according to Ostelo et al26 (positive test
injection with local anesthetics when a decrease in NRS of 2
or more on a 0 to 10 point scale is obtained) instead of a
decrease of 50% in NRS, using only local anesthetics
instead of corticosteroids and the probability that, based on
the diagnostic cascade used, the patients did not have SI
joint pain. The false-positive rate of a single, uncontrolled,
SI joint injection with local anesthetics is around 20%,2 but
can be as high as 54%.1 The local anesthetic diﬀuses out of
the joint in 61% of cases, becoming an intra-articular as
well as extra-articular injection.12
The presence of pain distal to the knee in patients with
SI joint pain is described but not often found and SI joint
denervation often will not relieve this type of pain when
present. Instead of using “sciatica (often S1)” as inclusion
criterion it would have been better to use “pain predom-
inantly below L5.” As stated the whole diagnostic cascade
should be taken into account and not a single item. Another
limitation of this study is the fact that we used only 1
diagnostic test block instead of using a double diagnostic
test block. Having considered the daily practice in pain
management, this sham RCT was completed with 1 diag-
nostic test block.
Regarding the internal validity of this study: (1)
Because of the anatomy of the sacrum, we sometimes did
not reach the S4 branch with the RF probe with 3 inde-
pendent active electrodes, performing a L5 to S3 RF pro-
cedure. How much does the S4 branch attribute to SI joint
pain? The size of the lesion by the RF probe with 3 inde-
pendent active electrodes might be smaller than the one
from the cooled RF treatment variant39 but, again, what is
the (exact) inﬂuence of that? (2) Age was non-normally
(bimodally) distributed (Fig. 3); this might reﬂect diﬀer-
ences in disease type, encompassing diﬀerent structures
(anatomic changes, disorders of the capsuloligamentous
structures, and diastasis from pregnancy and childbirth and
disorders from the vascular plexus or complex neural net-
work), and operative procedures.1,5 (3) Pain scores were
measured during follow-up at speciﬁc time periods
(Table 3). Using average pain scores over certain time
FIGURE 3. Boxplot of numerical rating scale (NRS)-11 scores by
group and by moment of measurement (verum= treatment
group; falsus = sham group).
TABLE 5. Numerical Rating Scale (NRS) and Global Perceived Effect (GPE) Scales of the Treatment and Sham Groups
Mean (SD)
Outcome Parameters Treatment Group Sham Group Results MANOVAs
NRS
T0
7.2 (1.4) 7.5 (1.2) Group
Period
F1,58=0.212; P=0.65
F1,58=61.76; P<0.001
F1,58=0.353; P=0.56
NRS
T1
5.4 (1.7) 5.4 (1.9) GroupPeriod
GPE satisfaction
T1
3.2 (1.1) 3.3 (1.0) Group
Period
F1,50=2.02; P=0.16
F1,50=0.95; P=0.33
F1,50=2.1; P=0.15
GPE satisfaction
T2
3.1 (1.6) 3.8 (1.5) GroupPeriod
GPE recovery
T1
3.3 (1.0) 3.3 (1.0) Group
Period
F1,50=0.004; P=0.95
F1,50=0.27; P=0.60
F1,50=0.09; P=0.77
GPE recovery
T2
3.4 (1.6) 3.4 (1.5) GroupPeriod
MANOVA indicates multivariate analysis of variance; T0, day of ﬁrst consultation; T1, 1 month after treatment; T2, 3 months after treatment.
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periods (ie, past month), based on pain diaries might have
led to a diﬀerent result. (4) All patients received graded
activity36,37 physiotherapy, but not at a single center; as a
consequence gaining evidence of equal quality of physi-
otherapy accompaniment was diﬃcult and we therefore do
not know whether—and if so to which extend—this factor
has confounded the treatment outcome.
On the basis of this RCT the hypothesis of no diﬀer-
ence in pain reduction or in GPE between the treatment
and sham group cannot be rejected (level of evidence 1A40).
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